Gossamer Bio (GOSS) Projected to Post Quarterly Earnings on Tuesday

Posted by Denise Randall on Feb 25th, 2025

Gossamer Bio (NASDAQ:GOSS – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $7.02 million for the quarter.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $1.30 on Tuesday. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.60. The business has a 50 day simple moving average of $1.03 and a two-hundred day simple moving average of $0.93. The stock has a market capitalization of $294.58 million, a PE ratio of -4.06 and a beta of 1.81.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research report on Thursday, January 30th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $9.20.

Check Out Our Latest Stock Analysis on Gossamer Bio

Institutional Trading of Gossamer Bio

A hedge fund recently raised its stake in Gossamer Bio stock. Bank of America Corp DE raised its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 107.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,788 shares of the company’s stock after buying an additional 43,866 shares during the period. Bank of America Corp DE’s holdings in Gossamer Bio were worth $77,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 81.23% of the stock is owned by institutional investors.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.